Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Plasma sex hormone-binding globulin is a potential biomarker of prodromal Alzheimer's disease
Aging, Dementia, and Behavioral Neurology
P5 - Poster Session 5 (8:00 AM-9:00 AM)
10-008

To investigate whether plasma sex hormone-binding globulin (SHBG) could predict Alzheimer’s disease (AD) biomarker and clinical progression in prodromal AD.
Sex hormone-binding globulin (SHBG) in plasma was significantly elevated in subjects with Alzheimer’s disease (AD) than their matched controls. SHBG is one of corticosteroid binding globulins (CBG) that deliver sex hormones in plasma to the outside of cells where some steroids are detached, internalized into the target cells, and bound to the intracellular receptors. It was hypothesized that the breach of equilibrium between the bound and free state might disturb the normal functioning of sex steroids. Moreover, it was found that the physiological response of mice to corticosteroid was decreased when the CBG expression was genetically suppressed, indicating that SHBG might also modulate the physiologic effects of its steroid cargos. Thus, it could be postulated that plasma SHBG might passively and actively influence neuroprotective functioning of steroids and further the risk of dementia or cognitive decline

Associations were investigated between plasma SHBG and AD biomarkers at baseline in non-demented Chinese adults. The values of plasma SHBG in predicting longitudinal changes of AD biomarkers, cognitive decline, and AD risk in non-demented adults were investigated using Alzheimer’s disease Neuroimaging Initiative (ADNI) database.

SHBG levels were highly related in plasma and CSF. Among non-demented Chinese adults, plasma SHBG was associated with lower levels of cerebrospinal fluid (CSF) Abeta42 (p < 0.005). In ADNI, higher levels of plasma SHBG were associated with greater rate of CSF Abeta42 decrease (p < 0.0005), brain metabolism decline (p < 0.05), hippocampus atrophy (p < 0.01), cognitive decline (p < 0.01), and higher risk of AD (p < 0.05).

Plasma SHBG shows promise as a potential noninvasive biomarker associated with neurodegeneration in prodromal AD.
Authors/Disclosures
Wei Xu
PRESENTER 		No disclosure on file